Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
NASH - Nonalcoholic Steatohepatitis
Clinical Trial
NCT05039450Last updated: 12/4/2025
AKRO
Akero Therapeutics, Inc.